Skip to Main Content
Pitt Home
Find People
School of Medicine
Toggle navigation
Skip Navigation Links
Home
Current Students
Current Student Roster
Student Publications
Diversity, Accessibility, and Counseling
Accessibility
Student Awards
MPGP News
Student Poster and Presentation Resources
Prospective Students
Welcome from the Director
Research Opportunities
PhD Track
MD/PhD Track
Financial Aid
Graduate Faculty
Admin Staff
Graduate Courses
Lab Rotations
Events
Grad Student Event Calendar
Graduate Student Event Schedule
Alumni/Career Development
Alumni
Alumni Contacts
Molecular Pharmacology Facebook Group
Molecular Pharmacology Student-Alumni Network (LinkedIn)
SOM Graduate Studies - Career and Professional Development
Executive Committee
Student Testimonials
IBGP
Funding Opportunities
NIH T32 Training Grant
Outcomes
Predoctoral Fellowship
Admissions
Student Handbook & General Timeline
Links
Useful Links
School of Medicine
PubMed
Remote Resources
Pharmacology & Chemical Biology
Molecular Pharmacology Graduate Program
>
Current Students
>
MPGP News
>
Translational Research in the News - Palladino
Follow @Pitt_Pharm_PhD
8/28/2019
Translational Research in the News - Palladino
Pharmacology and Chemical Biology professor Michael Palladino's work on metabolic diseases featured in WTAE story about child with TPI deficiency
Professor & Vice Chair for Faculty Affairs
Michael Palladino's
work on metabolic diseases was recently featured in a
WTAE story
about 11-month old JT Borofka, his parents, his
triosephosphate isomerase (TPI) deficiency
, and their hope for a cure.
Dr. Palladino's lab studies metabolic diseases including TPI deficiency. Their approach is multidisciplinary using genetics, biochemistry, pharmacology and structural biology. They’ve genetically engineered Drosophila to develop numerous animal models of TPI Df and have used these models to study disease pathogenesis, the basis of progressive neurologic dysfunction and conducted genome-wide screens that identified disease suppressors. These suppressors define numerous novel therapeutic pathways and the researchers in Dr. Palladino's lab are actively working to identify drug therapies for TPI Df. To support this goal they have developed stable human HEK cells and a high-throughput, semi-automated compound screening platform. They also have obtained several human patient cell lines to validate disease mechanisms and compounds identified using their drug screening platform.